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LOWERING PRESCRIPTION DRUG COSTS: A SMALL,
REGULATORY CHANGE WITH A LARGE,
LASTING IMPACT
I.

INTRODUCTION

“We have access to the greatest medicines in the world, but access
is meaningless without affordability.”1

This quote from former Department of Health and Human Services
(HHS) Secretary Alex Azar describes the current healthcare system in
the United States, with specific reference to the challenges this country faces regarding the cost of prescription drugs.2 In response to this
issue, former President Trump created a plan in 2018 aimed to reduce
soaring prescription drug prices and save consumers out-of-pocket
drug costs.3 This blueprint began as a proposal (Proposed Rule) by
HHS proposed on February 6, 2019, titled Fraud and Abuse; Removal
of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for
Certain Point-of-Sale Reductions in Price on Prescription
Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees4 but was publicly withdrawn only months later in July 2019 (although, HHS never officially withdrew the Proposed Rule from the
Federal Register).5 A year later, though, nearing the conclusion of former President Trump’s term in November 2020, the Proposed Rule
was finalized (Final Rule).6
1. HHS, AMERICAN PATIENTS FIRST 5 (May 2018), https://www.hhs.gov/sites/default/files/
AmericanPatientsFirst.pdf [hereinafter AMERICAN PATIENTS FIRST]; Jacqueline LaPointe, HHS
Secretary Alex Azar Resigns, Effective Jan. 20, REVCYCLE INTELLIGENCE (Jan. 19, 2021), https://
revcycleintelligence.com/news/hhs-secretary-alex-azar-resigns-effective-jan.-20 (“Alex Azar has
resigned as head of HHS to make room for President-elect Joe Biden’s pick for HHS Secretary
following his inauguration on Jan. 20, 2021.”).
2. LaPointe, supra note 1.
3. Id.
4. See generally Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving
Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-ofSale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, 85 Fed. Reg. 76,666 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
5. HHS, FACT SHEET: TRUMP ADMINISTRATION FINALIZES PROPOSAL TO LOWER DRUG
COSTS BY TARGETING BACKDOOR REBATES AND ENCOURAGING DIRECT DISCOUNTS TO PATIENTS 5 (2020), https://www.hhs.gov/about/news/2020/11/20/fact-sheet-trump-administration-finalizes-proposal-to-lower-drug-costs.html [hereinafter FACT SHEET: TRUMP ADMINISTRATION
FINALIZES PROPOSAL]; see infra King & Spalding, note 89 and accompanying text.
6. See generally 85 Fed. Reg. 76,666.
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As the title of the Proposed Rule states, and as was kept in the title
of the Final Rule, this rule establishes four changes to the regulatory
safe harbor protections to the federal Anti-Kickback statute (AKS) of
the Social Security Act.7 The AKS is a criminal law that “prohibits
transactions intended to induce or reward referrals for items or services reimbursed by the federal healthcare programs.”8 The purpose
of the AKS is to protect federal healthcare program beneficiaries
from being influenced by monetary bribes for referral decisions and,
in effect, is intended to prevent overutilization, increased costs, and
poor quality services.9 However, there are currently safe harbor regulations in place that permit discounts from manufacturers for prescription drugs provided to plan sponsors under Medicare Part D.10 Thus,
the Final Rule excludes from the definition of safe harbor protection
certain reductions in price or other remunerations offered by a prescription drug manufacturer to Medicare Part D plan sponsors or
pharmacy benefit managers (PBM).11
These offerings are similar to a bribe, discussed in further detail
below, and the costs were previously reflected in the amount that
Medicare Part D beneficiaries paid for their prescriptions. Thus, eliminating these bribes from safe harbor protection effectively lowers prescription drug prices since those hidden costs can no longer be tagged
onto the price that beneficiaries pay. Although amending this regulation may seem like a minor change, its effect can have a large impact
on creating more transparency in prescription drug costs for Americans and can effectively lower those costs.
Part II of this Comment reviews the many components involved in
understanding this Final Rule and its effect. First, it discusses Medicare in general and then more specifically, Medicare Part D and its
intended beneficiaries. Next, Part III provides a summary of the PBM
life cycle and rebates under the AKS. Finally, all of this background
information leads to the main focus of this Comment: the Proposed
Rule, which later turned into the Final Rule, and the effect that it will
have on lowering prescription drug prices for Medicare Part D beneficiaries. This Comment concludes by examining the positive effects the
Final Rule will have on beneficiaries.
7. Id. at 76,666; see Social Security Act, 42 U.S.C. § 1320a-7b (2018).
8. Thomas S. Crane et al., What Is the Anti-Kickback Statute?, A.B.A., https://
www.americanbar.org/groups/young_lawyers/publications/tyl/topics/health-law/what-is-antikickback-statute/ (last visited Mar. 27, 2021); see 42 U.S.C. § 1320a-7b(b).
9. Crane et al., supra note 8.
10. See 85 Fed. Reg. at 76,666.
11. Id.
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II. BACKGROUND
A. What is Medicare?
Medicare is a federal health insurance plan program.12 It was enacted in 1965 as “Health Insurance for the Aged” under Title XVIII
of the Social Security Act, originally intended as health coverage for
those over the age of sixty-five.13 Seven years later, in 1972, Medicare
expanded to additionally cover individuals under the age of sixty-five
who have disabilities and those with end-stage renal disease, which is
permanent kidney failure.14 It is evident through these three categories of people who qualify for coverage that Medicare is intended to
benefit the elderly, those who suffer from a health issue, or both.
Thus, each part of Medicare, Parts A, B, C, and D, provides different
types of health insurance to its beneficiaries.
Medicare Part D is a voluntary prescription drug plan for citizens
that use Medicare for their health insurance.15 Although Medicare
Part D is offered as a way for beneficiaries to obtain their necessary
prescription drugs at a lower cost, Part D beneficiaries endured higher
out-of-pocket costs in 2020 and 2021 than they have in previous
years.16 The Proposed Rule, introduced in February of 2019, was designed to combat these soaring prices for beneficiaries as an attempt
to provide more transparency by eliminating the hidden, additional
cost of rebates that gets added into the cost which consumers pay for
their prescription drugs.17 Initially, the Proposed Rule was withdrawn.18 This withdrawal was unfortunate for Medicare Part D beneficiaries because the Proposed Rule would have allowed seniors and
individuals with disabilities who rely on Medicare Part D to obtain the
prescription drugs they need, and it would have increased access to
12. MEDICARE.GOV, What’s Medicare?, https://www.medicare.gov/what-medicare-covers/
your-medicare-coverage-choices/whats-medicare (last visited Apr. 12, 2022).
13. Presentation from Ctrs. for Medicare & Medicaid Servs., Introduction to Medicare 5 (Apr.
4, 2022).
14. Id.
15. KAISER FAM. FOUND., An Overview of the Medicare Part D Prescription Drug Benefit
(Oct. 13, 2021), https://www.kff.org/medicare/fact-sheet/an-overview-of-the-medicare-part-d-prescription-drug-benefit.
16. Id.
17. HHS, FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS BY
TARGETING BACKDOOR REBATES AND ENCOURAGING DIRECT DISCOUNTS TO PATIENTS 2
(2019), https://www.hhs.gov/sites/default/files/20190131-fact-sheet.pdf [hereinafter FACT SHEET:
TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS].
18. Yasmeen Abutaleb et al., Trump Kills Key Drug Price Proposal He Once Embraced,
WASH. POST (July 11, 2019), https://www.washingtonpost.com/business/economy/white-housekills-key-drug-pricing-rule-to-eliminate-hidden-rebates/2019/07/11/ff595192-a3de-11e9-bd56eac6bb02d01d_story.html.
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more affordable healthcare. Although the Proposed Rule was finalized in 2020, implementation has been delayed until 2023; thus, beneficiaries cannot reap the benefits of the Final Rule for another year
and will continue paying inflated drug costs until then.
B. Medicare Part D: Prescription Drug Coverage
Among the sixty-two million Medicare users across the United
States, over forty-eight million are enrolled in Medicare Part D
plans.19 Part D was not originally a part of the Medicare plan enacted
in 1965. It was not until 2003 that former President George W. Bush
signed the Medicare Prescription Drug, Improvement, and Modernization Act, which added a prescription drug plan to Medicare and is
now known as Medicare Part D.20
The Medicare Part D plan covers many of the prescription drugs
commonly taken by people with Medicare, including drugs in certain
protected classes, such as drugs to treat cancer or HIV/AIDS.21 To
obtain Medicare Part D prescription drug coverage, beneficiaries have
two options.22 One option is to select a Medicare drug plan, which
essentially adds drug coverage to the beneficiary’s existing plan, such
as Original Medicare.23 Obtaining a separate Medicare drug plan requires pre-existing Medicare Part A or Medicare Part B coverage.24
The second option to get Part D coverage is through a Medicare Advantage Plan, which is Part C, or some other Medicare health plan
with drug coverage included.25 Similar to the first option, this requires
being enrolled in both Parts A and B.26
The price of prescription drugs can be costly, especially for those
who qualify for Medicare, since they are of older age or may have
disabilities, both of which can lead to an increased risk of additional
health problems that require additional prescription drugs.27 Prior to
19. KAISER FAM. FOUND., supra note 15.
20. Thomas R. Oliver et al., A Political History of Medicare and Prescription Drug Coverage,
82 MILBANK Q. 283, 283 (2004).
21. MEDICARE.GOV, How to Get Prescription Drug Coverage, https://www.medicare.gov/drugcoverage-part-d/how-to-get-prescription-drug-coverage (last visited Apr. 14, 2022).
22. Id.
23. Id.
24. Id.
25. Id.
26. Id.
27. HEALTH POL’Y INST., Prescription Drugs, https://hpi.georgetown.edu/rxdrugs (last visited
Mar. 27, 2021). Out-of-pocket prescription drug costs are much higher for older beneficiaries:
Annual average out-of-pocket prescription drug expenditures for all adults are $177,
but people age 65 and older pay much more for their medications. People age 65 to 79
pay $456 out-of-pocket. People age 80 and older pay even more . . . . Consumers who
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the enactment of Part D, tens of thousands of Medicare beneficiaries
had little assistance with drug costs, spending up to thousands of dollars each year out-of-pocket for prescription drugs.28 Thus, Medicare
Part D is insurance that covers these prescription drug costs and alleviates some of the burden on those who need these drugs.29 Although
Medicare Part D is a great resource, the high cost of prescription
drugs in the United States still remains a major issue.30
C. Pharmacy Benefit Manager Life Cycle
PBMs play an important role in the life cycle of prescription drugs
by acting as a middleman between the drug manufacturer and the consumer, who, for purposes of this Comment, is the Medicare Part D
beneficiary.31 PBMs are “companies that manage prescription drug
benefits on behalf of health insurers, Medicare Part D drug plans,
large employers, and other payers.”32 Essentially, PBMs serve as the
middleman in the distribution chain of prescription drugs between the
drug manufacturers, insurers, pharmacies, and consumers, such as
Medicare Part D beneficiaries.
PBMs work for insurance companies, big employers, and government agencies, and a large part of their job is to decrease the cost of
drugs for their employers.33 However, while PBMs aim to lower drug
costs for their employers, they simultaneously raise prices for consumers. Under the current PBM business model, “PBMs’ profit incentive
often conflicts with efforts to minimize drug costs for drug plans and
beneficiaries and, instead, can lead to higher drug prices for all pahave common chronic conditions have substantial prescription drug expenses. Since
their total prescription drug expenditures are very high, their total out-of-pocket expenditures are also high. They pay about half of the cost of prescription drugs out-ofpocket.
Id.
28. BOOMER BENEFITS, What is Part D?, https://boomerbenefits.com/medicare-part-d-plans/
what-is-part-d/ (last visited Apr. 14, 2022); MEDICARE.GOV, Costs in the Coverage Gap, https://
www.medicare.gov/drug-coverage-part-d/costs-for-medicare-drug-coverage/costs-in-the-coverage-gap (last visited Apr. 14, 2022) (out-of-pocket costs are defined as “[h]ealth or prescription
drug costs that you must pay on your own because they aren’t covered by Medicare or other
insurance”).
29. See BOOMER BENEFITS, supra note 28; MEDICARE.GOV, supra note 21.
30. See HEALTH POL’Y INST., supra note 27.
31. Michael Bihari, Pharmacy Benefit Managers Help Fill Your Prescriptions, VERYWELL
HEALTH (June 2, 2020), https://www.verywellhealth.com/pharmacy-benefit-manager-1124201.
32. COMMONWEALTH FUND, Pharmacy Benefit Managers and Their Role in Drug Spending
(Apr. 22, 2019), https://www.commonwealthfund.org/publications/explainer/2019/apr/pharmacybenefit-managers-and-their-role-drug-spending.
33. Ydejesus, How Drug Prices Work, WALL ST. J. (May 28, 2019, 6:00 AM), https://
www.wsj.com/video/how-drug-prices-work/C9D3F950-DFE3-4E37-9120-836D411A9A66.html.
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tients.”34 To put into perspective how large of an impact this adverse
business model has on consumers, PBMs currently manage drug benefits for over ninety percent of Americans with prescription drug coverage, meaning nearly all Medicare Part D beneficiaries are impacted by
this.35
There are three general ways that a PBM gets paid.36 A PBM can
either charge for administering benefits to a defined group of enrollees; collect rebates by negotiating with pharmaceutical manufacturers;
or receive the difference between what their clients pay for a drug and
what the pharmacy receives, which is known as “the spread.”37 The
focus of this Comment is on the second avenue: rebates. Pharmaceutical drug manufacturers pay rebates to PBMs for many of the drugs
they sell, and in turn, the PBM sometimes keeps a portion of the rebate or immediately distributes it to their employer, explained further
below.38
PBMs use formularies, which is a list of both brand name and generic prescription drugs, that are covered by a given health insurance
plan.39 These formularies determine which drugs individuals under
that health insurance plan will use, and they also determine the individuals’ out-of-pocket costs.40 Thus, drug manufacturers want to ensure that their drugs are covered by these formularies in order to
reach consumers that need them.41
D. How Rebates Work
The PBM formularies are where rebates come into play. Formularies have tiers of drugs that determine different levels of payment for
the consumer depending on the tier: “drugs in the lowest tier have the
smallest patient cost-sharing, while the drugs in the highest tier have
34. Joanna Shepherd, Pharmacy Benefit Managers, Rebates, and Drug Prices: Conflicts of Interest in the Market for Prescription Drugs, 38 YALE L. & POL’Y REV. 360, 361 (2020).
35. Id. at 361.
36. Ike Brannon et al., INSIGHT: Constraining Pharmacy Benefit Managers Will Not Reduce
Drug Prices, BLOOMBERG L. (Jan. 6, 2020, 3:00 AM), https://news.bloomberglaw.com/pharmaand-life-sciences/insight-constraining-pharmacy-benefit-managers-will-not-reduce-drug-prices.
37. Id.
38. Ydejesus, supra note 33.
39. Id.
40. Id.; See Elizabeth Davis, Why Isn’t This Prescription Drug on My Health Plan’s Drug
Formulary?, VERYWELL HEALTH (May 16, 2021), https://www.verywellhealth.com/why-isnt-myrx-drug-on-my-health-plan-drug-formulary-1738477 (“Many people are shocked to learn their
health plan has a list of drugs it will pay for . . . . [I]f your drug isn’t on that list, your health
insurance won’t pay for it.”).
41. What Is a Pharmacy Benefit Manager (PBM) and How Does a PBM Impact the Pharmacy
Benefits Ecosystem?, TRUVERIS (Feb. 17, 2021), https://www.truveris.com/resources/what-is-apbm-and-how-does-a-pbm-impact-the-pharmacy-benefits-ecosystem.
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the highest patient cost-sharing.”42 In other words, consumers pay
more for the lowest tier drugs and pay less for the highest tier drugs
because plans cover a greater portion of the drug cost as the tier level
increases.43 Due to the lack of transparency in this current PBM-controlled system, “payers are left out of the equation while expensive,
yet highly rebateable, drugs are placed in preferred positions on the
PBM formulary.”44
When a drug manufacturer offers a higher rebate to the PBM, the
PBM will move the drug up on the formulary to a higher tier, which
manufacturers desire because patients are more likely to choose the
drugs in higher tiers that will cost them less.45 This demonstrates how
status on the formulary can greatly increase the sales of a drug, which
creates competition among manufacturers to offer the largest rebates
to PBMs to ensure their drug gets listed on the formulary.46
For example, if a consumer wants a drug that is either in a lower tier
or not on the formulary at all, the consumer must pay a higher co-pay
for that drug.47 Thus, a manufacturer that pays a rebate to the PBM in
order to be placed higher on the PBM’s formulary will likely increase
sales of that drug since drugs in higher tiers cost the consumer less
money, resulting in the consumers being more likely to purchase those
drugs, as opposed to purchasing a lower tier drug which will cost the
consumer more out-of-pocket. To compensate for the cost of this rebate paid to the PBM, the drug manufacturer inflates the list price of
its drugs.48 And who bears the burden of this additional cost? The
consumer.
There is a positive correlation between rebates and the list price of
a drug.49 “On average, a $1 increase in rebates is associated with a
$1.17 increase in list price.”50 Some argue that PBMs are to blame for
rising drug prices since the PBMs’ increase in demand for rebates in
42. A Consumer Guide to Drug Formularies: Understanding the Fundamentals of Behavioral
Health Medications, PARITYTRACK, https://www.paritytrack.org/issue-briefs/a-consumer-guideto-drug-formularies-understanding-the-fundamentals-of-behavioral-health-medications/#parti:—prescription-drug-formulary-overview (last visited Apr. 14, 2022).
43. Id.; Ydejesus, supra note 33.
44. Lindsey Roberts, How Expensive Prescription Drugs Make It to the PBM Formulary,
RXBENEFITS (Oct. 20, 2020), https://www.rxbenefits.com/blogs/how-expensive-rx-drugs-makeformulary/.
45. Ydejesus, supra note 33.
46. See Shepherd, supra note 34, at 361.
47. Id.
48. Id.
49. Neeraj Sood et al., The Association Between Drug Rebates and List Prices, USC SCHAEFFER (Feb. 11, 2020), https://healthpolicy.usc.edu/research/the-association-between-drug-rebatesand-list-prices/.
50. Id.
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turn causes manufacturers to increase list prices to remain profitable
due to the higher costing rebates.51 Hence, it is a continuous cycle.
Due to the positive correlation between rebates and drug list prices,
“reducing or eliminating rebates could result in lower list prices,
thereby decreasing out-of-pocket costs for uninsured patients and for
insured patients with deductibles or coinsurance,” such as Medicare
Part D beneficiaries.52 Therefore, by excluding rebates from safe harbor protection under the AKS, this rule will benefit consumers as well
as drug manufacturers because it will save both parties the additional
cost that rebates are currently imposing on the list price of prescription drugs.53 This is especially true for consumers such as Medicare
Part D beneficiaries, who might enroll in such a program specifically
for the purpose of obtaining lower prescription drug prices.54
E. The Proposed Rule
On February 6, 2019, the Office of Inspector General (OIG) and
HHS proposed a rule titled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals
and Creation of New Safe Harbor Protection for Certain Point-of-Sale
Reductions in Price on Prescription Pharmaceuticals and Certain
Pharmacy Benefit Manager Service Fees to amend the safe harbor
regulation regarding discounts under the AKS, which is section
1128B(b) of the Social Security Act.55 The Proposed Rule subsequently was withdrawn on July 10, 2019, according to the White
House Office of Management and Budget,56 but the Proposed Rule
was never withdrawn from the Federal Register.57
The AKS is a law that, among other functions, criminalizes soliciting or receiving any remuneration, including rebates.58 Remuneration
51. Id.
52. Id.
53. Id.
54. MEDICARE.GOV, supra note 12.
55. See generally Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving
Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-ofSale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, 85 Fed. Reg. 76,666 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
56. Debra A. McCurdy, HHS Scraps Pending Rule to Remove Anti-Kickback Safe Harbor
Protection for Drug Rebates to Health Plans, PBMs, REED SMITH (July 12, 2019), https://
www.healthindustrywashingtonwatch.com/2019/07/articles/other-health-policy-developments/
other-oig-developments/hhs-scraps-pending-rule-to-remove-anti-kickback-safe-harbor-protection-for-drug-rebates-to-health-plans-pbms/; OIRA Conclusion of EO 12866 Regulatory Review,
OFF. OF INFO. & REG. AFF. (July 10, 2019), https://www.reginfo.gov/public/do/
eoDetails?rrid=129208.
57. FACT SHEET: TRUMP ADMINISTRATION FINALIZES PROPOSAL, supra note 5, at 5.
58. Social Security Act, 42 U.S.C. § 1320a–7b (2018).
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can include “anything of value and can take many forms besides cash,
such as free rent, expensive hotel stays and meals, and excessive compensation for medical directorships or consultancies.”59 Essentially,
remuneration is similar to a bribe, where something is either offered
or received due to a benefit incurred in return. While some industries
permit rewarding others for providing a benefit, paying for referrals is
a crime in the federal healthcare programs.60 Violations of this statute
are not taken lightly; penalties include fines, jail terms, and exclusion
from participation in the federal healthcare program.61
Upon announcing the Proposed Rule, HHS indicated that its intention was for drug “manufacturers to lower their list prices, replace rebates with discounts, or do both.”62 For example, beneficiaries who do
not fill some of their prescriptions because of expensive out-of-pocket
costs would be more likely to fill them if their prices were lower,
which would occur under the Proposed Rule.63
Although it appears that the AKS should apply to the rebates that
PBMs charge drug manufacturers, since rebates are essentially a bribe
to get higher up on the PBM’s formulary, there are currently regulatory safe harbor protections in place which preclude the rebates from
criminal liability.64 Thus, the Proposed Rule was designed to “expressly exclude from safe harbor protection under the Anti-Kickback
statute (AKS) rebates on prescription drugs paid by manufacturers to
pharmacy benefit managers (PBMs), Part D plans, and Medicaid managed care organizations.”65 Essentially, the Proposed Rule, as well as
the Final Rule, amend the safe harbor regulation by excluding certain
reductions in price or other remuneration from a manufacturer to
plans under Medicare Part D, or PBMs under contract with them,
from the definition of a discount eligible for safe harbor protection.66
In sum, the Proposed Rule was an attempt to provide more transparency in prescription drug pricing by eliminating the hidden, addi59. Fraud & Abuse Laws, U.S. DEP’T OF HEALTH & HUM. SERVS., https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/ (last visited Apr. 14, 2022).
60. Id.
61. Id.
62. CONG. BUDGET OFFICE, INCORPORATING THE EFFECTS OF THE PROPOSED RULE ON SAFE
HARBORS FOR PHARMACEUTICAL REBATES IN CBO’S BUDGET PROJECTIONS—SUPPLEMENTAL
MATERIAL FOR Updated Budget Projections: 2019 to 2029 2 (2019), https://www.cbo.gov/system/
files/2019-05/55151-SupplementalMaterial.pdf [hereinafter INCORPORATING THE EFFECTS OF
THE PROPOSED RULE].
63. Id. at 4.
64. Crane et al., supra note 8.
65. FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS, supra note 17,
at 1.
66. 42 C.F.R. § 1001.952 (2020).
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tional cost of rebates that get added into the price that consumers pay
for their prescription drugs. Additionally, the Proposed Rule provided
for two new safe harbor provisions.67 The first would protect certain
point-of-sale reductions in price on prescription drugs, and the second
would protect certain PBM service fees.68 These proposed safe harbor
provisions were added as an incentive to offer prescription drug discounts directly to consumers and to create a fixed fee service arrangement between drug manufacturers and PBMs to provide transparency
in fees involved in transactions that have been kept secret from public
knowledge for far too long.69 Therefore, the Proposed Rule should
never have been withdrawn so that it could rid the system that is designed to provide more affordable drugs from inflating prescription
drug prices.
F. Issues with the Current Rebate System that Final Rule Seeks to
Combat
There are three main problems with the current rebate system in
place that the Proposed Rule, and subsequently, the Final Rule, seek
to correct.70 First and foremost, some beneficiaries undergo increased
financial burdens.71 This is because the current system rewards higher
list prices for prescription drugs; thus, the Final Rule seeks to protect
upfront discounts in order to combat the incentives for higher list
prices.72
The second problem is that the rebates which drug manufacturers
pay to PBMs to get on their formularies are not reflected in the price
of the out-of-pocket cost the Medicare beneficiary pays.73 Therefore,
the Final Rule amends the safe harbor regulations “to offer protection
for reductions in price that are reflected at the point of sale,” thus, the
rule “provide[s] a strong incentive for drug manufacturers to offer discounts that will directly benefit patients by lowering their out-of67. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees, 85 Fed. Reg. 76,666, 76,666 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
68. Id.
69. FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS, supra note 17,
at 1.
70. 85 Fed. Reg. at 76,668.
71. Id.
72. Id. at 76,666; With the current rebate system in place, if the negotiation between manufacturers and PBMs favors higher rebates over lower drug costs, then it results in higher list prices,
which is detrimental to Part D beneficiaries.
73. Id.
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pocket costs at the pharmacy counter.”74 This problem contributes to
the lack of transparency in prescription drug prices that the Final Rule
aims to correct.
Finally, a third problem of the current rebate system is that it discourages consumers’ use of low-priced generic drugs or biosimilars.75
This is due to the fact that insurers and Medicare Part D plan sponsors
can often receive higher rebates from brand name drugs and biologics,
which minimizes their incentive to use biosimilars.76 One solution to
this problem is for manufacturers of brand name drugs to decrease
generic or biosimilar competition by offering larger rebates when they
pay for a drug or group of drugs and make the payment of those rebates contingent upon maintaining their exclusive formulary position.
In effect, this would not only alleviate out-of-pocket costs for consumers, but it would also promote a free market system by increasing the
availability of drug options, rather than limit sources to only brand
name drugs.
G. Reasons the Proposed Rule was Withdrawn
When the Proposed Rule was initially introduced in February 2019,
it was withdrawn by July of that year, and “its advancement was hotly
contested.”77 The decision to withdraw the Proposed Rule was made
in July 2019 by former President Trump himself, nearly seven months
74. FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS, supra note 17,
at 2. For example, if the consumer is spending out-of-pocket up to his deductible, then the consumer pays the amount agreed to between the plan and the pharmacy, which is usually based at
least partially on the drug’s list price without regard for the rebates. Further, when a patient is
using coinsurance, the patient pays for the drug as a percentage of the amount agreed to between his plan and the pharmacy, which is also based on the plan’s list price for the drug. Additionally, in some instances, the consumer’s cost sharing may be higher than the net price paid by
his plan after rebates.
75. Id.; According to the Food and Drug Administration, a biosimilar is a biological product
which is a “[l]arge and generally complex molecule[ ],” that is “[p]roduced from living organisms,” and that is “[c]arefully monitored to ensure consistent quality.” What is a Biosimilar?,
FDA, https://www.fda.gov/media/108905/download (last visited Apr. 15, 2022). Biosimilars are
distinct from, but often confused with, generic drugs. “But biosimilar drugs and generic drugs are
very different, mainly because while generic drugs are identical to the original in chemical composition, biosimilar drugs are ‘highly similar,’ but close enough in duplication to accomplish the
same therapeutic and clinical result.” CANCER TREATMENT CTRS. OF AM., What’s the Difference? Biosimilar and Generic Drugs (Dec. 25, 2018), https://www.cancercenter.com/community/
blog/2018/12/whats-the-difference-biosimilar-and-generic-drugs.
76. FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS, supra note 17,
at 2; FACT SHEET: TRUMP ADMINISTRATION FINALIZES PROPOSAL, supra note 5, at 2.
77. Rachel Sachs, Administration Finalizes Drug Pricing Rebate Rule at The Last Minute,
HEALTH AFFS. (Nov. 23, 2020), https://www.healthaffairs.org/do/10.1377/hblog20201122.985836/
full/.
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after releasing the proposal.78 This begs the question: what changed?
Why would former President Trump, who vehemently advocated79 to
reduce the cost of prescription drugs, make the decision to withdraw
the proposal but then finalize it at the eleventh hour of his
presidency?80
The Proposed Rule was withdrawn in 2019 for two main reasons:
concerns regarding a substantial increase in federal spending, upwards
of nearly $180 billion over the following ten years, and the potential
risk of increasing Medicare beneficiaries’ premiums.81 According to
the Congressional Budget Office (CBO), this projection reflects the
assumption that pharmaceutical manufacturers would refuse to give
approximately fifteen percent of the discounts currently given to
PBMs in Medicare Part D, which would no longer be allowed under
the Proposed Rule.82 In effect, the CBO predicted that instead of decreasing the list price of the drugs, these manufacturers would offer
the renegotiated discounts as a chargeback.83
A pharmaceutical chargeback occurs in two scenarios.84 In the first,
a wholesaler purchases drugs from the pharmaceutical company at a
specified contract price and sells them to consumers at a different contract price.85 When the consumer contract price is less than the pharmaceutical price, the wholesaler will charge the pharmaceutical
company this difference in price to prevent loss of profit.86 The second
scenario involves a chargeback resulting from a failed transaction in
which the entire payment made by the consumer must be returned to
the consumer.87 The Proposed Rule aimed to eliminate Medicare Part
D beneficiaries’ current cost-sharing obligation, which is related to the
list price of the drug and does not include the rebates paid by the
78. Abutaleb et al., supra note 18.
79. AMERICAN PATIENTS FIRST, supra note 1, at 9.
80. See generally Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving
Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-ofSale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, 85 Fed. Reg. 76,666 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
81. Sachs, supra note 77; INCORPORATING THE EFFECTS OF THE PROPOSED RULE, supra note
62, at 1.
82. INCORPORATING THE EFFECTS OF THE PROPOSED RULE, supra note 62, at 2 (These projections were made prior to the rule being finalized in 2020).
83. Id. at 2–3. “Manufacturers could offer discounts to beneficiaries either by reducing their
list price or by making a payment to the pharmacy of the full amount of the negotiated discount
(referred to as a chargeback).” Id. at 2.
84. Tyler Lacoma, What Is a Pharmaceutical Chargeback?, BIZ FLUENT (Nov. 21, 2018), https:/
/bizfluent.com/info-8783464-pharmaceutical-chargeback.html.
85. Id.
86. Id.
87. Id.
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manufacturer to either the PBM or private plan.88 Rather, the Proposed Rule replaced it with a cost-sharing model that instead is based
on an overall lower list price for the drug or on a post-chargeback
price.89 Therefore, Part D beneficiaries would be provided with more
transparency as well as lower drug prices.
H. The Final Rule
The Final Rule was created on November 20, 2020, shortly before
former President Trump’s term ended and shortly after the presidential election, and it is essentially the Proposed Rule from February
2019 with some modifications.90 Although the government publicly
withdrew the rule, an official notice of withdrawal was never listed in
the Federal Register.91 Therefore, HHS’s OIG finalized the Proposed
Rule, establishing the Final Rule.92 The rebate system in place prior to
the enactment of the Final Rule has been described as “opaque,”
which is evidenced by the issues discussed above.93 This is because the
old rebate system did not reflect to consumers the hidden costs in the
price they were paying at the point of sale for their prescription drugs;
therefore, the new system under the Final Rule will offer true discounts.94 Thus, the Proposed Rule was initially created, and later finalized,95 to combat this issue by “expressly excluding rebates on
88. INCORPORATING THE EFFECTS OF THE PROPOSED RULE, supra note 62, at 2. This is part of
the problem. Although this cost is not directly reflected in the price, the inflation of the costs
represents the hidden fees consumers are unknowingly paying to compensate for the rebates.
89. Id.
90. King & Spalding, HHS Finalizes Rule Challenging Drug Manufacturer Rebates to PBMs
and Payors, JD SUPRA (Nov. 30, 2020), https://www.jdsupra.com/legalnews/hhs-finalizes-rulechallenging-drug-89523/; Angelica LaVito, White House Drops Proposal to Eliminate Drug Rebates. Health Stocks Soar, CNBC (July 11, 2019, 8:06 AM), https://www.cnbc.com/2019/07/11/
white-house-pulls-proposal-to-eliminate-drug-rebates-politico.html (“[T]he Congressional
Budget Office found the rule would cost $177 billion through 2029.”); Sachs, supra note 77 (“Another point is worth making about the differences (or, really, lack thereof) between the NPRM
and final rule.”).
91. Sachs, supra note 77.
92. See generally Medicare and Medicaid Programs; Contract Year 2022 Policy and Technical
Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program,
Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the
Elderly, 86 Fed. Reg. 5864 (Jan. 19, 2021) (to be codified at 42 C.F.R. pts. 405, 417, 422–23, 255,
460).
93. FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS, supra note 17,
at 1.
94. Id.
95. Two rules regarding drug-pricing were actually finalized:
One rule creates a Most Favored Nation (“MFN”) Model that seeks to lower prices by
indexing Medicare Part B payments for the top 50 physician-administered drugs to
prices paid by other countries. The second rule focuses on the Medicare Part D program, replacing the current federal anti-kickback safe harbor protection for manufac-
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prescription drugs paid by manufacturers to pharmacy benefit managers (PBMs) and Part D plans from safe harbor protection under the
Anti-Kickback Statute (AKS).”96 The current rebate system in place,
outlined in Trump’s May 2018 drug pricing blueprint, has a domino
effect by incentivizing higher list prices for prescription drugs, which
benefits the PBMs and, in turn, increases the costs for patients.97
Initially, the Final Rule was supposed to go into effect on January
29, 2021, except for the amendments to 42 C.F.R. 1001.952(h)(5),
which were to become effective on January 1, 2022.98 The Final Rule
retains the same title as the Proposed Rule.99 But as of current, the
entire Final Rule will not go into effect until January 1, 2023, prolonging implementation for an additional two years.100
There were several significant changes made to the Proposed Rule
before it was finalized, which are demonstrated in the Final Rule. As
previously mentioned, prescription drug prices have been described as
“opaque,”101 and according to Centers for Medicare and Medicaid
Services (CMS) Administrator Seema Verma, the changes made from
the Proposed Rule to the Final Rule “provide desperately needed
transparency on the out-of-pocket costs for prescription drugs that
turer rebates to Part D plan sponsors and their contracted Pharmacy Benefit Managers
(“PBMs”) with a new safe harbor limited to rebates that benefit patients at the pharmacy counter.
Michael Gallagher & Kevin C. Adam, Trump Administration’s Eleventh-Hour Drug Pricing Regulations Face an Uncertain Path Forward, WHITE & CASE (Dec. 3, 2020), https://
www.whitecase.com/publications/alert/trump-administrations-eleventh-hour-drug-pricing-regulations-face-uncertain-path.
96. The New Regulation for Drug Rebates in Medicare Part D, ENSURE DATA SOLUTIONS,
https://ensuredatasolutions.com/the-new-regulation-for-drug-rebates-in-medicare-part-d/ (last
visited Apr. 12, 2022).
97. AMERICAN PATIENTS FIRST, supra note 1, at 12.
98. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees; Delayed Effective Date, 86 Fed. Reg. 10,181, 10,181 (Feb. 19, 2021).
99. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees, 85 Fed. Reg. 76,666, 76,666 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
100. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees; Additional Delayed Effective Date, 86 Fed. Reg. 15132, 15132–33 (Mar. 22, 2021) (to be
codified at 42 C.F.R. pt. 1001).
101. FACT SHEET: TRUMP ADMINISTRATION PROPOSES
17, at 1.

TO

LOWER DRUG COSTS, supra note
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have been obscured for seniors.”102 This demonstrates the importance
of the Proposed Rule being finalized and one of its most positive effects: to provide Medicare Part D beneficiaries, who are primarily senior citizens, with information on what they are actually paying for
when they pick up their prescriptions from the pharmacy.
First, the Final Rule’s effective date changed, pushing it back two
years to allow entities affected by the rule to properly prepare.103 Additionally, the Final Rule offers protection to the price reductions that
are offered to Medicare Part D plan sponsors or Medicaid Managed
Care Organizations (MCOs), contingent upon where the drug is
placed on the PBM formulary.104 This protection is offered under the
new safe harbor for point-of-sale reductions in price under 42 C.F.R.
§ 1001.952(cc).105 Further, these reductions in price offered to Medicaid MCOs that are also contingent upon where the drug is placed in
the formulary will remain protected by the discount safe harbor at 42
C.F.R. § 1001.952(h).106 Therefore, despite the Final Rule’s efforts to
primarily benefit the Part D beneficiaries, the Final Rule still includes
benefits for plan sponsors and MCOs. Another change is that the Final Rule does not amend 42 C.F.R. § 1001.952(h) to exclude rebates
offered to Medicaid MCOs, which is the discount safe harbor provision, with the caveat that rebates that are offered by pharmaceutical
manufacturers to Medicaid MCOs satisfy all other safe harbor requirements.107 The final major change from the Proposed Rule to the
Final Rule is a change in the definition of a “chargeback.”108 This revi102. Changes to Medicare Advantage and Part D Will Provide Better Coverage, More Access
and Improved Transparency for Medicare Beneficiaries, CMS.GOV (Jan. 15, 2021), https://
www.cms.gov/newsroom/press-releases/changes-medicare-advantage-and-part-d-will-providebetter-coverage-more-access-and-improved.
103. 86 Fed. Reg. at 15132–33.
104. Epstein Becker & Green, Finalized HHS Drug Formulary Rebate Rule Faces Uncertain
Future Under Biden Administration and Current Legal Challenge, JD SUPRA (Jan. 18, 2021),
https://www.jdsupra.com/legalnews/finalized-hhs-drug-formulary-rebate-5473810/.
105. AMERICAN PATIENTS FIRST, supra note 1, at 22; 42 C.F.R. § 1001.952(cc).
106. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees, 85 Fed. Reg. at 76,667 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
107. Id. at 76,717.
108. FACT SHEET: TRUMP ADMINISTRATION FINALIZES PROPOSAL, supra note 5, at 6. For further explanation on this change in definition under the Final Rule:
We proposed to define a “chargeback” as a payment from a manufacturer to a dispensing pharmacy that would be at least equal to the discounted price of the drug agreed to
by the manufacturer and the Part D Plan sponsor or Medicaid MCO. We agree with
commenters who noted that our proposed definition could lead to gaming and that the
chargeback should be equal to the reduction in price, not the discounted price of the
drug, so we define a chargeback in the final rule as a payment equal to the reduction in
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sion was in response to commenters, and the Final Rule will rename it
a “point-of-sale chargeback.”109
In response to concerns of increased federal spending and premiums for Medicare Part D beneficiaries, former HHS Secretary Alex
Azar stated his belief that these increases would not occur, which follows from HHS’s expectation that manufacturers will lower list prices
of drugs in response.110 This belief is also supported by CMS, which
explained that the changes between the Proposed Rule and Final Rule
“are expected to result in an estimated $75.4 million savings to the
federal government over ten years, arising exclusively from Drug
Management Program (DMP) savings on reduced prescription drug
spending.”111
III.

ANALYSIS

Finalizing the Proposed Rule was the proper decision made in order
to rid a system that is designed to provide more affordable drugs from
ever-inflating prescription drug prices. The Final Rule and its various
amendments to 42 C.F.R. § 1001.952 may seem like minor changes,
but the impact those changes will have on Medicare Part D beneficiaries is major.
A. PBM Opposition to the Final Rule
Some potential roadblocks to implementing the Final Rule have already been flagged by various sources.112 While figures from both political parties demonstrated support and excitement for the Final Rule
passing, other politicians expressed concern for the rule being passed
price. This definition ensures that the pharmacy is made whole for the difference between acquisition cost, plan payment, and beneficiary out-of-pocket payment.
Id.
109. 85 Fed. Reg. at 76,697–98.
110. Sachs, supra note 77.
111. Contract Year 2022 Medicare Advantage and Part D Final Rule (CMS-4190-F2) Fact
Sheet, CMS.GOV (Jan. 15, 2021), https://www.cms.gov/newsroom/fact-sheets/contract-year-2022medicare-advantage-and-part-d-final-rule-cms-4190-f2-fact-sheet.
112. See Gallagher & Adam, supra note 95. Many believe that the Final Rule is going to be
subject to lawsuits from industry stakeholders and other political challenges from those such as
the pharmaceutical industry, the PCMA, and America’s Health Insurance Plans (the insurance
industry trade association); Sachs, supra note 77. Ricardo Alonso-Zaldivar, Trump Makes LateTerm Bid to Lower Prescription Drug Costs, AP NEWS (Nov. 20, 2020), https://apnews.com/article/donald-trump-medication-prescription-drug-costs-medicare-prescription-drugs-e17119840
2445755b920842ded293b59 (“[I]n a time of political uncertainty, it’s hard to say whether the
rules will withstand expected legal challenges from the pharmaceutical industry or whether President-elect Joe Biden’s administration will accept, amend or try to roll them back entirely.”).
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so late in former President Trump’s term.113 In fact, the Pharmaceutical Care Management Association (PCMA), a trade group that represents PBMs, filed suit against joint defendants which includes HHS,
OIG, Counsel to OIG, Department of Justice, and individuals working under all of those organizations, such as former HHS Secretary
Alex Azar, to challenge implementation of the Final Rule.114 The
complaint filed by the PCMA sought declaratory and injunctive relief,
including asking the U.S. District Court for the District of Columbia
to declare the Final Rule unlawful and to vacate and set aside the
Final Rule.115 Amidst the many allegations cited in this complaint, the
PCMA claimed that the Final Rule would “increase prescription drug
premiums, federal spending, and aggregate spending on prescriptions—ultimately harming the American seniors and disabled citizens
the Rule purports to help.”116 On January 30, 2021, the court issued an
order stating that the PCMA and HHS must both “submit a joint status report identifying whether and how this case should proceed by
not later than April 1, 2021.”117 Eventually, the PCMA pulled their
lawsuit after coming to a resolution with the Biden administration.118
In addition to filing this complaint, the PCMA created a report in
2019, before the Proposed Rule was withdrawn, conducted by Matrix
Global Advisors that “suggests there is limited evidence supporting
the claim that rebates are tied to higher list prices and that the plan
does not properly target the [sic] Department of Health and Human
Services’ (HHS) stated goals.”119 Amongst other criticisms in this report, the Matrix Global Advisors note that HHS strayed from its typical practice by relying on its own actuarial analysis conducted by the
113. Gallagher & Adam, supra note 95; Yasmeen Abutaleb, Trump Pushes Last-Minute Drug
Pricing Rules Likely to Face Big Legal Challenges, WASH. POST (Nov. 20, 2020), https://
www.washingtonpost.com/health/2020/11/20/trump-drug-price-rules/. Senator Mark R. Warner
called the Final Rule “a significant step in the right direction for improving patient care.” Id. On
the other hand, Representative Lloyd Doggett referred to the Final Rule as an “invitation to
legal challenges” due to how late in his presidency Trump finalized the rule. Id.
114. Complaint at 1, Pharm. Care Mgmt. Ass’n v. U.S. Dep’t of Health and Human Servs.,
No. 1:21-CV-02161 (D.D.C. Dec. 1, 2021).
115. Id. at 78.
116. Complaint at 2, Pharm. Care Mgmt. Ass’n v. U.S. Dep’t of Health and Human Servs.,
No. 1:21-CV-00095 (D.D.C. Jan. 12, 2021).
117. Order at 1, Pharm. Care Mgmt. Ass’n v. U.S. Dep’t of Health and Human Servs., No. 2195 (D.D.C. Jan. 30, 2021).
118. Robert King, PCMA Pulls Lawsuit Over Rebate Disclosure Rule After Reaching Deal
with Biden Admin, FIERCE HEALTHCARE (Dec. 2, 2021), https://www.fiercehealthcare.com/
payer/pcma-pulls-lawsuit-over-rebate-disclosure-rule-after-reaching-deal-biden-admin.
119. Jacqueline Renfrow, PCMA Report Says HHS Rebate Rule Would Significantly Boost
Drug, Part D Spending, FIERCE HEALTHCARE (Apr. 8, 2019, 6:42 AM), https://
www.fiercehealthcare.com/payer/pcma-calls-proposed-drug-rebates-rule-poorly-conceived.
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CMS Office of the Actuary and also by contracting with two privatesector firms to determine the impact of the Proposed Rule.120 This
report insinuates that HHS, by deviating from its standard practice
and, additionally, by having two private-sector firms formulate the impact of the Proposed Rule, bent the rules and thus utilized inaccurate
data to support the Proposed Rule. The claims in this report created
by Matrix Global Advisors for the PCMA are baseless since they do
not state what standard practice is in either case or what alternative
method HHS should have used to determine the Proposed Rule’s
impact.
In addition to the litigation that has ensued, there is uncertainty
surrounding the Final Rule and what the Biden administration may do
with it now that he has been inaugurated. President Biden nominated
Xavier Becerra as the new Secretary of the HHS.121 The Senate voted
to confirm Becerra for this role on March 18, 2021, despite opposition
from Republicans.122 This will add another interesting wrinkle in former President Trump’s decision to finalize the rule at the conclusion
of his presidential term. However, Becerra has actually “openly expressed concerns with the impact of formulary rebates on competition
and drug prices.”123 Therefore, the Final Rule may be subject to stay
under his new direction, following former HHS Secretary Alex Azar.
B. Arguments that Withdrawal Should Preclude Finalization
In further opposition of the Final Rule, some have argued that since
the Proposed Rule was withdrawn, an agency “cannot proceed directly to the final rule stage (as it did here) if it changes its mind about
the withdrawal.”124 This is because once withdrawn, a rule can only
recommence by issuing another notice of proposed rulemaking before
120. ALEX BRILL, CONCERNS REGARDING THE PROPOSED RULE TO RESTRICT DRUG MANUREBATES IN MEDICARE PART D AND MEDICAID MCOS 2 (2019), http://getmga.com/
wp-content/uploads/2019/04/MGA-Report-on-Proposed-Rebate-Restriction-3.pdf (This report
and claims were made regarding the Proposed Rule and not the Final Rule; thus, some numbers
may not be an accurate reflection of the impact of the Final Rule due to changes made from
when it was initially proposed.).
121. Lois M. Collins, Xavier Becerra’s Future Role in Your Family Life, DESERETNEWS (Jan.
23, 2021, 10:00 PM), https://www.deseret.com/indepth/2021/1/23/22226637/what-role-will-xavierbecerra-play-in-family-health-human-services-secretary-biden-administration. Becerra has had
several roles throughout his career, including providing legal aid services to low-income families,
serving in Congress for twenty-four years, and serving as the Attorney General of California. Id.
Notably, as President Biden’s nominee, Becerra would be the first Hispanic to head HHS. Id.
122. Allison Pecorin, Xavier Becerra confirmed as HHS Secretary over Republican Opposition, ABC NEWS (Mar. 18, 2021, 12:19 PM), https://abcnews.go.com/Politics/xavier-becerra-confirmed-hhs-secretary-republican-opposition/story?id=76518625.
123. Epstein Becker & Green, supra note 104.
124. Sachs, supra note 77.
FACTURER
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being finalized.125 Essentially, once a rule is officially withdrawn, it is
as if the rule never existed, and lawmakers must start from the very
beginning again before proceeding.
This claim is also baseless. The Proposed Rule was never officially
withdrawn since it was never reported in the Federal Register.126
Thus, this combats the claim that once a rule is withdrawn it cannot be
finalized because, here, the Proposed Rule was never subject to an
official withdrawal noted in the Federal Register.127 Therefore, it was
unnecessary to reintroduce the Proposed Rule before finalization
since it was never officially listed as withdrawn. In response, those
opposing the Final Rule further argue that the actions of the administration constitute a withdrawal and should thus be treated as one, regardless of whether it was officially recorded in the Federal
Register.128 Regardless of whether the Proposed Rule was actually
withdrawn, many are also concerned about the precedent this may set,
citing instances in which administrations claim to withdraw a controversial rule and then finalize the rule immediately after an election.129
Despite some opposition to the Final Rule, finalizing the Proposed
Rule was the correct choice made by HHS. There are numerous potential benefits that can result from the Final Rule not only for Medicare Part D beneficiaries, but also for the prescription drug market as
a whole. As described in the blueprint created by the Trump administration prior to the Proposed Rule, the Final Rule can have the effect
of boosting competition and enhancing negotiation in addition to the
primary goals of creating incentives for lower list prices and reducing
out-of-pocket spending.130 Thus, the Final Rule can actually benefit
125. Id.
126. John O’Brien & Kelly Cleary, Are We Gearing Up for a Drug Rebate Rule Instant
Replay?, EVIDENCE BASE (July 21, 2020), https://healthpolicy.usc.edu/evidence-base/are-wegearing-up-for-a-drug-rebate-rule-instant-replay/ (“The decision to withdraw a proposed rule after a notice and comment period is considered ‘final agency action.’. . . Interestingly, there was
no such notice for the rebate rule.”).
127. See generally Bridget C.E. Dooling, Going Through Regulatory Withdrawal, YALE J. ON
REG. (Oct. 13, 2020), https://www.yalejreg.com/nc/going-through-regulatory-withdrawal/.
128. Id.
129. Dan Bosch, Zombie Rebate Rule Could Create Troubling Precedent, INSIGHT (Aug. 25,
2020), https://www.americanactionforum.org/insight/zombie-rebate-rule-could-create-troublingprecedent/. The finalization of this rule is the first time in recent history that a rule was announced as withdrawn then came back without being re-proposed. Id. As a result, finalizing this
rule sets precedent that could “destabilize the regulatory process,” and in the future there may
be similar occurrences in which similar moves are made for political gain. Id.
130. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees, 85 Fed. Reg. 76,666, 76,666 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
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drug manufacturers as well and incentivize innovation in the prescription drug market due to increased efforts in competition and
negotiations.
IV. IMPACT
A. The Final Rule’s Lasting Effect
The Final Rule makes four small regulatory changes to 42 C.F.R.
§ 1001.952 that will widely benefit Medicare Part D beneficiaries once
the Final Rule goes into effect in 2023.131 The amendment to 42
C.F.R. § 1001.952(h)(5) that removes from safe harbor protection reductions in price for prescription pharmaceutical products provided to
Part D plan sponsors will likely have the greatest impact for consumers.132 This will increase transparency in drug pricing by preventing
manufacturers from offering discounts to PBMs and compensating for
those discounts by increasing the list price of their drugs, which consumers have no choice but to pay under the current rebate system.
Although this amendment seems like a small, technical change, its effect on prescription drug pricing overall will save Medicare Part D
beneficiaries money on drugs, which is the purpose of a Part D
plan.133
In addition to saving beneficiaries money, this Final Rule can also
potentially decrease government spending in Medicare Part D.134 For
example, plan sponsors subtract rebates from their plan bids, and
lower bids result in lower premiums, which in turn can result in lower
government spending on premium subsidies.135
B. Positive Effects of Final Rule on Medicare Part D Beneficiaries
Despite the few groups that are unhappy with the Final Rule, which
primarily consist of the PBMs, the Final Rule carries great benefits to
Medicare Part D beneficiaries. As mentioned in Part I, Medicare Part
D is intended to benefit those who are either elderly or suffer from a
131. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees; Additional Delayed Effective Date, 86 Fed. Reg. 15132, 15133 (Mar. 22, 2021) (to be codified at 42 C.F.R. pt. 1001).
132. 42 C.F.R. § 1001.952(h)(5).
133. An Overview of the Medicare Part D Prescription Drug Benefit, supra note 15.
134. 86 Fed. Reg. at 15133.
135. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription
Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service
Fees, 85 Fed. Reg. 76,666, 76,667 (Nov. 30, 2020) (to be codified at 42 C.F.R. pt. 1001).
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health issue.136 The Final Rule requires drug manufacturers to give
Medicare rebates to the Medicare beneficiaries rather than to insurers
or PBMs, which is where the rebates currently end up.137 In other
words, the discount will be reflected in the price that consumers, the
Medicare beneficiaries, pay, rather than the insurers or PBMs, who
currently benefit from the rebates. Although the CBO claims this
would increase taxpayer costs by nearly $180 billion over the next decade, the Trump administration supported the rule and estimated that
it could actually result in thirty percent savings for Medicare Part D
beneficiaries.138
At the time of this writing and prior to the Proposed Rule being
finalized, Medicare Part D premiums were already predicted to increase nine percent from thirty-eight dollars in 2020 to forty-one dollars in 2021.139 These numbers are demonstrated further in a bar chart
that shows a steady increase in the price of premiums from the year
2006 through 2021.140
V.

CONCLUSION

So, what exactly does all of this mean for Medicare Part D beneficiaries? The Final Rule’s more transparent discounts are anticipated
to lead to decreased spending for Part D beneficiaries overall.141 This
is due to the projected decrease in out-of-pocket costs for the beneficiaries being greater than the potential increase in premiums.142 Further, while savings will vary by beneficiary, beneficiaries who are the
sickest or who have more expensive prescription drugs are likely to
save the most.143 This means that Medicare Part D will fulfill its intended goal: to benefit those who are sick and/or the elderly, a group
that can be interchangeable with those who pay higher drug costs.144
After reviewing average prescription drug prices in the United
States, it is easy to see why former President Trump took the initiative
136. See supra Part II.
137. Alonso-Zaldivar, supra note 112.
138. Id.
139. Juliette Cubanski & Anthony Damico, Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2021, KAISER FAM. FOUND. (Oct. 29, 2020), https://www.kff.org/medicare/issue-brief/medicare-part-d-a-first-look-at-medicare-prescription-drug-plans-in-2021/.
140. Id. at fig. 3.
141. Id.
142. Id.
143. Id.
144. Id.; FACT SHEET: TRUMP ADMINISTRATION PROPOSES TO LOWER DRUG COSTS, supra
note 17, at 3 (“The new system would work as insurance is intended to: where those with especially high out-of-pocket drug costs will be most likely to benefit.”).
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to lower prescription drugs.145 What is still unclear, though, is why this
proposal was made, debatably withdrawn, and subsequently finalized
the following year, which happened to be immediately following the
2020 presidential election. Regardless of the resulting litigation and
other potential effects of this Final Rule discussed in this Comment,
the goal remains the same: to decrease prescription drug prices for
Medicare Part D beneficiaries, as they are members of a program designed to perform this objective.
Nicole Mouzakiotis

145. Robert Langreth, Drug Prices, BLOOMBERG (Sept. 16, 2020, 12:13 PM), https://
www.bloomberg.com/quicktake/drug-prices (highlighting how on average, Americans spend
more on prescription drugs than any other country in the world, which is due to higher prices in
the United States than other countries worldwide); Report: U.S. Drug Prices Far Exceed Average
for 11 Similar Countries, AM. HOSP. ASS’N (Sept. 23, 2019, 2:58 PM), https://www.aha.org/news/
headline/2019-09-23-report-us-drug-prices-far-exceed-average-11-similar-countries (“U.S. drug
prices are nearly four times higher than the combined average price for 11 other similar
countries.”).

